

Form PTO-1449  INFORMATION DISCLOSURE STATEMENT				Attorney's Docket No. GNE-0321C2		Application Serial No. 10/010,245	
(use several sheets if necessary)				Applicant(s)  Carter		Group Art Unit: 1645	
				Filing Date: December 7, 2001			
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.						
	2.						
	3.						
	4.						
	5.						
	6.						
	7.						
	8.						
	9.						
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES      NO
<b>OTHER DOCUMENTS</b> (including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
	1.	Abstract: Jefferies, et al. <i>IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation</i> , Immunot. Rev. 1998 June; 163:59-76					
	2.	Thies, et al.; <i>Folding and association of the antibody domain CH3: prolyl isomerization precedes dimerization</i> , J. Mol. Biol. 1999 Oct. 15; 293(1):67-79					

LIBC 3556408 1  
09/26/2008

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. *If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	